Table 1.
Baseline characteristics
| Baseline | OTG | MITG | P-value | ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Number of patients | 49 | 47 | |||
| Age at time of surgery | 61.8 | 10.0 | 59.4 | 12.5 | 0.298 |
| Gender (male %) | 32 | 65.3% | 28 | 59.6% | 0.674 |
| ASA classificationa | |||||
| ASA 1 | 6 | 12.2% | 4 | 8.5% | 0.813* |
| ASA 2 | 31 | 63.3% | 30 | 63.8% | |
| ASA 3 | 12 | 24.5% | 13 | 27.7% | |
| Tumor location | |||||
| Proximal | 14 | 28.6% | 12 | 28.9% | 0.999* |
| Middle | 25 | 51.0% | 23 | 51.1% | |
| Distal | 10 | 20.4% | 9 | 20.0% | |
| Clinical T-stage | |||||
| T1 | 1 | 2.0% | 2 | 4.3% | 0.730* |
| T2 | 8 | 16.3% | 9 | 19.1% | |
| T3 | 36 | 73.5% | 30 | 63.8% | |
| T4 | 4 | 8.2% | 6 | 12.8% | |
| Clinical N-stage | |||||
| N0 | 17 | 34.7% | 17 | 36.2% | 0.711* |
| N1 | 25 | 51.0% | 26 | 55.3% | |
| N2 | 7 | 14.2% | 4 | 8.5% | |
| Neoadjuvant chemotherapy | |||||
| ECC | 12 | 24.5% | 9 | 19.1% | 0.690* |
| ECF | 10 | 20.4% | 9 | 19.1% | |
| EOX | 13 | 26.5% | 13 | 27.7% | |
| Folfox | 0 | 2 | 4.3% | ||
| FLOT | 10 | 20.4% | 8 | 17.0% | |
| Other | 4 | 8.2% | 6 | 12.8% | |
*Additional testing within groups with Bonferroni correction showed no differences between groups
aAmerican society of anesthesiologists (ASA)